Reliance Life Sciences Private Limited — FDA Compliance Timeline

FDA action counts

Enforcement history

On 2026-07-15, Argus HQ recorded an FDA recall for Reliance Life Sciences Private Limited, rated "high" severity in Argus HQ's classification: Reliance Life Sciences Private Limited — Class II recall: Pemetrexed for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For in…. On 2026-07-15, Argus HQ recorded an FDA recall for Reliance Life Sciences Private Limited, rated "high" severity in Argus HQ's classification: Reliance Life Sciences Private Limited — Class II recall: Pemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For in…. On 2026-07-15, Argus HQ recorded an FDA recall for Reliance Life Sciences Private Limited, rated "high" severity in Argus HQ's classification: Reliance Life Sciences Private Limited — Class II recall: Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For S…. On 2026-07-15, Argus HQ recorded an FDA recall for Reliance Life Sciences Private Limited, rated "high" severity in Argus HQ's classification: Reliance Life Sciences Private Limited — Class II recall: Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous…. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Reliance Life Sciences Private Limited has 4 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

What is the most recent FDA action against Reliance Life Sciences Private Limited?

The most recent FDA event Argus HQ has on file for Reliance Life Sciences Private Limited is dated 2026-07-15, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Reliance Life Sciences Private Limited automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Reliance Life Sciences Private Limited is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for Reliance Life Sciences Private Limited?

4 total: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for Reliance Life Sciences Private Limited?

July 15, 2026. Argus HQ ingests new FDA enforcement records daily.

Related enforcement actions

• Reliance Life Sciences Private Limited — Class II recall: Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous… →
• Reliance Life Sciences Private Limited — Class II recall: Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For S… →
• Reliance Life Sciences Private Limited — Class II recall: Pemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For in… →
• Reliance Life Sciences Private Limited — Class II recall: Pemetrexed for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For in… →

Compare with

• Reliance Life Sciences Private Limited vs Philips North America
• Reliance Life Sciences Private Limited vs Boston Scientific Corporation
• Reliance Life Sciences Private Limited vs Medline Industries, LP
• Reliance Life Sciences Private Limited vs Baxter Healthcare Corporation
• Reliance Life Sciences Private Limited vs PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.